Fig. 1: Individual treatment courses and parameters of immune function.

a The vertical axis represents absolute neutrophil counts (ANC), blue boxes show treatment regimen and duration (RVe rituximab, venetoclax, GVe obinutuzumab, venetoclax, GIVe obinutuzumab, ibrutinib, venetoclax, FCR fludarabine, cyclophosphamide, rituximab). Infections after study inclusion and onset of COVID-19 are depicted in orange boxes. The threshold for neutropenia is shown in yellow. b The vertical axis shows levels of immunoglobulins before (baseline) and after treatment (final restaging), normal ranges are indicated in green. Each cross/line represents one patient. c Changes in T-cell subpopulations in the course of first-line treatment. Patients on venetoclax combinations are depicted in black, the patient on FCR is shown in orange. Blue bars represent median values of all analyzed patients at each time point.